[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553882":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":94,"collaborators":7,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":7,"enrollmentInfo":106,"targetDuration":7,"studyType":109,"phases":7,"briefSummary":110,"conditions":111,"keywords":7,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[15,29,34,44,53,62,69,74,79,84,89],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"Research Site","NOT_YET_RECRUITING","Belo Horizonte","Minas Gerais","30110-934","Brazil","BR",{"type":24,"coordinates":25},"Point",[26,27],-43.93778,-19.92083,{"lat":27,"lon":26},{"facility":16,"status":17,"city":18,"state":19,"zip":30,"country":21,"countryCode":22,"cosmosGeoPoint":31,"geoPoint":33,"contacts":7},"30380-420",{"type":24,"coordinates":32},[26,27],{"lat":27,"lon":26},{"facility":16,"status":35,"city":36,"state":37,"zip":38,"country":21,"countryCode":22,"cosmosGeoPoint":39,"geoPoint":43,"contacts":7},"RECRUITING","Natal","Rio Grande do Norte","59062-000",{"type":24,"coordinates":40},[41,42],-35.20944,-5.795,{"lat":42,"lon":41},{"facility":16,"status":17,"city":45,"state":46,"zip":47,"country":21,"countryCode":22,"cosmosGeoPoint":48,"geoPoint":52,"contacts":7},"Porto Alegre","Rio Grande do Sul","90560-032",{"type":24,"coordinates":49},[50,51],-51.23019,-30.03283,{"lat":51,"lon":50},{"facility":16,"status":17,"city":54,"state":55,"zip":56,"country":21,"countryCode":22,"cosmosGeoPoint":57,"geoPoint":61,"contacts":7},"São José do Rio Preto","São Paulo","15090-000",{"type":24,"coordinates":58},[59,60],-49.37944,-20.81972,{"lat":60,"lon":59},{"facility":16,"status":35,"city":55,"state":7,"zip":63,"country":21,"countryCode":22,"cosmosGeoPoint":64,"geoPoint":68,"contacts":7},"01308-050",{"type":24,"coordinates":65},[66,67],-46.63611,-23.5475,{"lat":67,"lon":66},{"facility":16,"status":17,"city":55,"state":7,"zip":70,"country":21,"countryCode":22,"cosmosGeoPoint":71,"geoPoint":73,"contacts":7},"01323-001",{"type":24,"coordinates":72},[66,67],{"lat":67,"lon":66},{"facility":16,"status":35,"city":55,"state":7,"zip":75,"country":21,"countryCode":22,"cosmosGeoPoint":76,"geoPoint":78,"contacts":7},"01323-020",{"type":24,"coordinates":77},[66,67],{"lat":67,"lon":66},{"facility":16,"status":35,"city":55,"state":7,"zip":80,"country":21,"countryCode":22,"cosmosGeoPoint":81,"geoPoint":83,"contacts":7},"01333-010",{"type":24,"coordinates":82},[66,67],{"lat":67,"lon":66},{"facility":16,"status":17,"city":55,"state":7,"zip":85,"country":21,"countryCode":22,"cosmosGeoPoint":86,"geoPoint":88,"contacts":7},"01509-010",{"type":24,"coordinates":87},[66,67],{"lat":67,"lon":66},{"facility":16,"status":35,"city":55,"state":7,"zip":90,"country":21,"countryCode":22,"cosmosGeoPoint":91,"geoPoint":93,"contacts":7},"05652-900",{"type":24,"coordinates":92},[66,67],{"lat":67,"lon":66},{"type":95,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100553882","race-2l-real-world-assessment-of-clinical-practice-and-outcomes-in-non-squamous-nsclc-after-failure-of-platinum-based-chemotherapy-in-brazil-100553882",false,"NCT06491862","RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil","RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil","RACE-2L","Inclusion Criteria\n\n* Confirmed diagnosis of patients with non-squamous NSCLC stage IIIB\u002FIIIC not eligible for curative-intent therapies or stage IV\u002FM1 (a\u002Fm NSCLC) with or without actionable genomic mutations (i.e., EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, RET, HER-2)\n* Aged at least 18 years at first diagnosis of a\u002Fm NSCLC\n* For the AGA subgroup, having received platinum-based chemotherapy, having received at least one target approved therapy.\n* For the non\\_AGA subgroup,should have received either sequential or concurrent use of ICI and PTC)\n* Patient must have received at least line of therapy of an active agent after failing PTC.\n\nExclusion Criteria\n\n* Patients with evidence of other primary malignancies (apart from basal cell carcinoma and melanoma) within 1 year prior to the index date will be excluded from both the study cohorts.\n* Patients who participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2018 onward.","ALL","18 Years",{"count":107,"type":108},250,"ESTIMATED","OBSERVATIONAL","The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a\u002Fm non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2024.",[112],"Non-squamous Non-Small Cell Lung Cancer","2026-06-19",{"date":115,"type":116},"2026-06-23","ACTUAL",{"date":118,"type":116},"2024-07-25",{"date":120,"type":108},"2026-06-30",{"name":5,"class":6},11]